Ardelyx shares are trading lower after the company announced that it has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease Prospective Payment System Transitional Drug Add-on Payment Adjustment.
Portfolio Pulse from Benzinga Newsdesk
Ardelyx shares are trading lower after the company announced it will not apply to include XPHOZAH in the CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-on Payment Adjustment.
July 02, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ardelyx shares are trading lower after the company announced it will not apply to include XPHOZAH in the CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-on Payment Adjustment.
The decision not to apply for XPHOZAH's inclusion in the CMS payment system likely signals potential revenue loss or slower revenue growth for Ardelyx, leading to a negative market reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100